FDA Extends Belite Drug Review for Stargardt Disease
The FDA extended its review of Belite Bio’s application for tinlarebant, an oral treatment for Stargardt disease type 1, by three months, setting a new action date of May 12, 2027. The agency said the additional time is to assess information submitted with the application and expects to communicate proposed labeling and any anticipated postmarketing requirements by April 12, if no major deficiencies arise. Tinlarebant is designed to reduce vitamin A transport to the eye and limit the buildup of toxic compounds linked to retinal damage; Belite says its Phase 3 trial met its primary endpoint. The delay pushed Belite shares lower and postpones a potential launch, while the drug is also being studied for Stargardt disease and geographic atrophy.





